Skip to main content
. 2022 Sep 13;32(2):183–192. doi: 10.1158/1055-9965.EPI-22-0712

Table 2.

Logistic regression analysis, endpoints hrHPV positivity, CIN 2+ and CIN 3+ (without and with imputation), all screened women.

Without imputation With imputation
Unadjusted model Unadjusted model Adjusted models
Model 1 Model 1 Model 2a Model 3b Model 4c Model 5d
(N = 864,810) (N = 857,866) (N = 857,866) (N = 857,866) (N = 857,866) (N = 857,866)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
hrHPV positivity
 Clinician-collected 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
 Self-sampling 0.80 (0.78–0.83) 0.80 (0.78–0.83) 0.67 (0.65–0.69) 0.73 (0.70–0.75) 0.73 (0.70–0.75) 0.65 (0.63–0.68)
CIN 2+
 Clinician-collected 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
 Self-sampling 0.82 (0.76–0.88) 0.96 (0.89–1.03) 0.73 (0.68–0.79) 0.81 (0.75–0.88) 0.81 (0.75–0.88) 0.76 (0.70–0.82)
CIN 3+
 Clinician-collected 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
 Self-sampling 0.96 (0.87–1.06) 1.12 (1.02–1.23) 0.83 (0.76–0.91) 0.92 (0.84–1.01) 0.92 (0.84–1.01) 0.86 (0.78–0.95)

Note: All cases with missing values for household income and/or screening region (0.8% of total cohort) are excluded from the analyses with imputation presented in this table. Ten rounds of imputation were used to replace missing CIN2+/CIN3+ endpoints for women with a hrHPV-positive self-sampling and no cytology result. Pooled ORs are presented for these endpoints. Pooled ORs with 95% CI not including 1.00 are shown in bold.

aAdjusted for screening history.

bAdjusted for screening history and age.

cAdjusted for screening history, age, and screening region.

dAdjusted for screening history, age, screening region, and sociodemographic characteristics.